ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1

Conditions

• Depressed Mood

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Study Details

This study will evaluate the feasibility and clinical utility of developing predictive models of treatment response for patients with depressed mood using multimodal clinical data collected in real-world clinical settings. The study will examine outcomes among patients treated with interventions including esketamine, conventional transcranial magnetic stimulation (TMS), or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT). Retrospective clinical and research data from existing databases may also be incorporated, when available and authorized, to support model development and validation. The goal is to assess whether integrated clinical datasets can be used to support the development of predictive tools that may inform personalized treatment selection in depression.

Key Dates

Start date

Mar 25, 2026

Status verified

Apr 2026

Primary completion

Mar 31, 2036

Completion

Mar 31, 2037

Study Design

Enrollment

5,000 participants (estimated)

Arms

• Arm: Esketamine
  Patients receiving esketamine for the treatment of depressed mood.
• Arm: Conventional rTMS
  Patients receiving conventional rTMS for the treatment of depressed mood.
• Arm: SAINT
  Patients receiving SAINT for the treatment of depressed mood.

Primary Outcome Measure

Patient Health Questionnaire 9-item (PHQ-9) [ Time Frame: Pre-treatment, Post-treatment, 2 weeks posttreatment, and Monthly post-treatment for 12 months ]

Locations (2)

Find similar trials in La Jolla, CA